Janux Therapeutics
JANX
47 hedge funds and large institutions have $407M invested in Janux Therapeutics in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 23 increasing their positions, 10 reducing their positions, and 4 closing their positions.
130% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 10
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
2% more funds holding
Funds holding: 46 → 47 (+1)
2.13% more ownership
Funds ownership: 66.08% → 68.21% (+2.1%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
25% less capital invested
Capital invested by funds: $542M → $407M (-$135M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$11.2M |
| 2 |
BlackRock
New York
|
+$2.51M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$2.05M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$895K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$549K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$3.65M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$1.01M |
| 3 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
-$892K |
| 4 |
Jane Street
New York
|
-$311K |
| 5 |
D.E. Shaw & Co
New York
|
-$267K |
JANX Hedge Fund Activity: Q1 2022 in Review
47 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q1 2022, worth a combined $407M — down 25% from $542M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new JANX positions and 4 closed out — a net gain of 1 holder — while 23 added to existing stakes and 10 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $11.2M. The largest seller was Logos Global Management, exiting entirely with an estimated $3.65M sold.
- 47 institutional investors held Janux Therapeutics (JANX) as of Q1 2022, up from 46 in Q4 2021.
- Funds reported $407M of Janux Therapeutics stock for Q1 2022, down 25% quarter-over-quarter.
- 5 funds opened new Janux Therapeutics positions in Q1 2022 and 4 closed out, a net change of +1 holder.
- The largest Janux Therapeutics buyer in Q1 2022 was Fidelity Investments, an estimated $11.2M added.
- The largest Janux Therapeutics seller in Q1 2022 was Logos Global Management, an estimated $3.65M sold.
Based on aggregated 13F filings for Q1 2022.